Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
COMMENTARY Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
-
ARCHIVE JCL Bioassay to Start "Cold" MD Studies
September 10, 2007
-
ARCHIVE Political Science Scholar with Personal
September 10, 2007
-
ARCHIVE NEW PRODUCTS/Daiichi Sankyo: Fentanyl for Infants
September 10, 2007
-
ARCHIVE RIKEN Kobe Institute to Develop
September 10, 2007
-
ARCHIVE Takeshi Erikawa Appointed
September 10, 2007
-
ARCHIVE Korosho to Train Senior CRCs, Data Managers, IRB Members
September 10, 2007
-
ARCHIVE Korosho to Demand \22,160.4 Bil., Up 3.2%, in FY2008
September 10, 2007
-
ARCHIVE Korosho to Standardize Forms for Clinical Trial Documents
September 10, 2007
-
ARCHIVE Japan's 1st Drug for ADHD Recommended for Approval
September 10, 2007
-
ARCHIVE R&D NEWS IN BRIEF
September 10, 2007
-
ARCHIVE Korosho to Create Council for Promotion of Generics in Each Prefecture
September 3, 2007
-
ARCHIVE JMA to Survey Medical Professionals' Views on Quality of Generics
September 3, 2007
-
COMMENTARY COMENTARY:Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
-
ARCHIVE Discussions Start for Revision of Ethical GL for Clinical Research
September 3, 2007
-
ARCHIVE SELF-MEDICATION NEWS IN BRIEF
September 3, 2007
-
ARCHIVE R&D NEWS IN BRIEF
September 3, 2007
-
ARCHIVE Daiichi Sankyo Ties Up with Forest Lab. for AZOR
September 3, 2007
-
ARCHIVE Japan Tissue Engineering's Autologous Epidermis Recommended for Approval
September 3, 2007
-
ARCHIVE Teijin to Codevelop Ipsen's ITM-077 with Chugai
September 3, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…